Skip to content

Cannabinoid Modulation of Pain

Cannabinoid Modulation of Pain

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01595620
Enrollment
6
Registered
2012-05-10
Start date
2011-11-09
Completion date
2012-04-19
Last updated
2022-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Cannabis, THC, Pain

Brief summary

The purpose of this study is to test the effects of cannabinoids on pain response using a variety of human experimental pain models.

Interventions

OTHERThermal

Thermal sensation/pain testing

Electrical sensation/pain testing

OTHERCapsaicin

Intradermal Capsaicin

DRUGTHC

Active THC (0.01 mg/kg) administered over 10 minutes

DRUGPlacebo

Control: small amount of alcohol with no THC, administered over 10 minutes

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* At least one lifetime exposure to cannabis * Acceptable Birth Control methods for females

Exclusion criteria

* Cannabis naive * Medical or psychiatric contraindications * Analgesic medication * Previous sensitivity to THC or cannabis

Design outcomes

Primary

MeasureTime frame
Capsaicin-induced hyperalgesiaOn each test day at baseline (-30), peak (+20) and post (+120) drug administration

Secondary

MeasureTime frame
Non-pain subjective responsesOn each test day at baseline (-30), peak (+20) and post (+120) drug administration
Pain MeasuresOn each test day at baseline (-30), peak (+20) and post (+120) drug administration
Cognitive subjective responsesOn each test day at baseline (-30), peak (+20) and post (+120) drug administration

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026